1. A composition for an anti-cancer vaccine for transdermal administration for use in the induction of cellular immunity, comprising: (i) a WT1 peptide and / or a modified WT1 peptide； and (ii) a cell immunity induction stimulator selected from a TLR ligand, a cyclic dinucleotide, a helper peptide, an immunomodulating low molecular weight drug, a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP production inhibitor, an acid inhibitor of 3, an inhibitor of an adrenergic antigen inhibitor PPAR, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, antago serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarinic receptor antagonist, muscarinic receptor agonist, adrenaline receptor antagonist, adrenaline receptor agonist, angiotensin receptor agonist, GABA receptor agonist, agonist receptor agonist, agonist agonist ADP, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, somatost receptor agonist tin, a cannabinoid receptor agonist, a sphingosine 1-phosphate receptor agonist, a glutamate metabotropic receptor agonist, a phospholipase A2 inhibitor, a TGF-β production inhibitor, a Th2 cytokine inhibitor, and a combination of two or more of these species. 2. The anti-cancer vaccine composition for transdermal administration according to claim 1, in which the composition is intended for use in1. Композиция противораковой вакцины для трансдермального введения для применения в индукции клеточного иммунитета, содержащая:(i) пептид WT1 и/или модифицированный пептид WT1； и(ii) стимулятор индукции клеточного иммунитета, выбранный из лиганда TLR, циклического динуклеотида, хелперного пептида, иммуномодулирующего низкомолекулярного лекарственного средства, ингибитора циклооксигеназы, антагониста рецептора простагландина, агониста рецептора простагландина,
